The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer

Table 1

Responses rates of women with epithelial ovarian cancer to olaparib (AZD2281) by platinum sensitivity in Phase I (Fong et al.) [26] and Phase II trials (Audeh et al.) [28].

	No. evaluable		Responders by RECIST (%)		Responders by RECIST or GCIG (%)
	Phase I [26]	Phase II [28]	Phase I [26]	Phase II [28]	Phase I [26]	Phase II [28]
Total	46	33	13 (28%)	11 (33%)	21 (46%)	20 (61%)
Platinum sensitive (>6 months)	10	7	5 (50%)	1 (14%)	8 (80%)	—
Platinum resistant (≤6 months)	25	26	8 (32%)	10 (38%)	11 (44%)	—
Platinum refractory	11	—	0 (0%)	—	2 (18%)	—